|
ACEI |
Angiotensin-converting enzyme inhibitor |
||
|
ACR |
American College of Rheumatology of SLE |
||
|
Adolopment |
Adoption-Adaptation-Development |
||
|
AGREE II |
Appraisal of Guidelines for Research and Evaluation Instrument |
||
|
AGBM |
Anti-glomerular basement membrane antibodies |
||
|
Atypical hemolytic uremic syndrome |
|||
|
AKI |
Acute kidney injury |
||
|
ANCA |
Antineutrophil cytoplasmic antibodies |
||
|
ANCAV |
ANCA vasculitis |
||
|
APS |
Anti-phospholipid syndrome |
||
|
ARBs. |
Angiotensin receptor blockers |
||
|
ASOT |
Antistreptolysin O titer |
||
|
AZA |
Azathioprine |
||
|
BMD |
Bone mineral disease |
||
|
C3/DDD |
Complement 3/dense deposit disease |
||
|
C3G |
Complement 3 glomerulopathy |
||
|
C3GN |
Complement 3 glomerulonephritis |
||
|
CR |
Complete remission |
||
|
CKD |
Chronic kidney disease |
||
|
CNI |
Calcineurin |
||
|
CPD |
Chronic peritoneal dialysis |
||
|
CPG |
Clinical Practice Guideline |
||
|
CRF |
Chronic renal failure |
||
|
CS |
Corticosteroid |
||
|
CSF |
Cerebrospinal fluid |
||
|
CYC |
Cyclophosphamide |
||
|
CYS R |
Cyclosporin resistant |
||
|
CVD |
Cardiovascular disease |
||
|
DDD |
Dense deposit disease |
||
|
DHS |
Demographic and Health Survey |
||
|
DMS |
Diffuse mesangial sclerosis |
||
|
EM |
Electron microscopy |
||
|
EMA |
European Medicines Agency |
||
|
EPG |
Egyptian Pediatrics Clinical Practice Guidelines Committee |
||
|
EPG CPG |
EPG Clinical Practice Guideline |
||
|
ERG |
External Review Group |
||
|
ESKD |
End-stage kidney disease |
||
|
ESRD |
End-stage renal disease |
||
|
EULAR |
European League Against Rheumatism/American College |
||
|
FR |
Frequent relapse |
||
|
FSGS |
focal and segmental glomerulosclerosis |
||
|
GAG |
Guideline Adaptation Group |
||
|
GDG |
Guideline Development Group |
||
|
GFR |
Glomerular filtration rate |
||
|
GIT |
Gastroenteritis |
||
|
GPS |
Good Practice Statement |
||
|
GRADE |
Grading of Recommendations Assessment, Development and Evaluation |
||
|
GT |
Genetic tests |
||
|
Glucocorticoids |
Steroids |
||
|
HBV |
Hepatitis B virus |
||
|
HCV |
Hepatitis C virus |
||
|
HIV |
Human immunodeficiency virus |
||
|
IF |
Immunofluorescopy |
||
|
IFTA |
Interstitial fibrosis tubular atrophy |
||
|
IgAV |
IgA vasculitis |
||
|
IgAN |
IgA nephropathy |
||
|
INR |
International formalized ratio |
||
|
IPNA |
International Pediatric Nephrology Association |
||
|
ISKDC |
International Study Kidney Disease in Children |
||
|
ISN/RPS |
International Society of Nephrology/Renal Pathology Society |
||
|
I.V |
Intravenous |
||
|
IV CYC |
Intravenous cyclophosphamide |
||
|
IV MP |
Intravenous methyl prednisone |
||
|
KDIGO |
Kidney Disease International Global outcome |
||
|
LM |
Light microscopy |
||
|
LN |
Lupus nephritis |
||
|
MCD |
Minimal change disease |
||
|
MCNS |
Minimal change nephrotic syndrome |
||
|
MDR |
Multidrug resistant |
||
|
mg/kg |
Milligram of medication per kilogram of body weight |
||
|
MMF |
Mycophenolate mofetil |
||
|
MN |
Membranous nephropathy |
||
|
MP |
Methylprednisolone |
||
|
MP |
Membranoproliferative |
||
|
NCGL |
National Clinical Guideline |
||
|
NGS |
Next-generation sequencing |
||
|
NS |
Nephrotic syndrome |
||
|
NS-GAG |
Nephrotic Syndrome Guideline Adaptation Group |
||
|
PICO |
population, intervention, comparison, and outcomes |
||
|
Patient population, intervention, professionals, outcomes, and healthcare context |
||
|
PDN |
Prednisone |
||
|
PE |
Plasma exchange |
||
|
PLA2R |
Phospholipase A2 receptor antibodies |
||
|
PNC |
Pediatric nephrology center |
||
|
PP |
Practice point |
||
|
PR |
Partial remission |
||
|
PSGN |
Post streptococcal glomerulonephritis |
||
|
RASI |
Renin angiotensin system inhibitor |
||
|
RIGHT |
A Reporting Tool for Practice Guidelines in Health Care |
||
|
RPGN |
Rapidly progressive glomerulonephritis |
||
|
SCr |
Serum creatinine |
||
|
SD |
Steroid dependent |
||
|
SLE |
Systemic lupus erythematosus |
||
|
SLEDAI |
Diffuse activity index for lupus patients |
||
|
SRNS |
Steroid resistant nephrotic syndrome |
||
|
SSNS |
steroid-sensitive nephrotic syndrome |
||
|
TMA |
Thrombotic microangiopathy |
||
|
TX |
Transplantation |
||
|
TTP |
Thrombotic thrombocytopenic purpura |
||
|
UPCR |
Urine protein creatinine ratio |
||
|
VZIG |
Varicella-zoster immune globulin |
||
|
WES |
Whole exon sequencing |
||
|
WGS |
Whole genome sequencing |